^
BTK C481S
CLL
SNS-062
Sensitive: D – Preclinical
Blood - 1 day
FLT3 mutation
Leukemia
midostaurin
Sensitive: C1 - Off-label
Eur J Haematol - 4 days
No biomarker
B Acute Lymphoblastic Leukemia
brexucabtagene autoleucel
Sensitive: A1 - Approval
Kite Pharma - 2 weeks
RUNX1 mutation
AML
venetoclax
Sensitive: C2 – Inclusion Criteria
Blood Adv - 2 weeks
TP53 mutation
Hairy Cell Leukemia
rituximab + cladribine
Resistant: C3 – Early Trials
Blood Adv - 2 weeks
No biomarker
CMML
decitabine/cedazuridine
Sensitive: A1 - Approval
Astex Press Release - 3 weeks
BCR-ABL1 fusion
CML
imatinib
Sensitive: A1 - Approval
Cureus - 3 weeks
NUP98-KDM5A fusion
AML
VTP-50469
Sensitive: D – Preclinical
Blood - 3 weeks
NUP98-NSD1 fusion
AML
VTP-50469
Sensitive: D – Preclinical
Blood - 3 weeks
CD20 positive
CLL
Truxima (rituximab biosimilar)
Sensitive: A1 - Approval
FLT3 mutation
AML
gilteritinib
Sensitive: A1 - Approval
IDH2 mutation
AML
enasidenib
Sensitive: A1 - Approval
No biomarker
AML
glasdegib
Sensitive: A1 - Approval
No biomarker
B Acute Lymphoblastic Leukemia
tisagenlecleucel-T
Sensitive: A1 - Approval
No biomarker
Childhood B Acute Lymphoblastic Leukemia
tisagenlecleucel-T
Sensitive: A1 - Approval
No biomarker
CLL
rituximab + ibrutinib
Sensitive: A1 - Approval
No biomarker
AML
azacitidine oral
Sensitive: A1 - Approval
No biomarker
AML
cytarabine/daunorubicin liposomal formulation
Sensitive: A1 - Approval
Chr del(17p)
CLL
venetoclax + obinutuzumab
Sensitive: A1 - Approval
TP53 mutation
CLL
venetoclax + obinutuzumab
Sensitive: A1 - Approval
No biomarker
CLL
venetoclax + obinutuzumab
Sensitive: A1 - Approval
BCR-ABL1 fusion
CML
dasatinib
Sensitive: A1 - Approval
No biomarker
CLL
ICP-022
Sensitive: A1 - Approval
FLT3 mutation
AML
midostaurin
Sensitive: A1 - Approval
CD33 positive
AML
gemtuzumab ozogamicin
Sensitive: A1 - Approval
BCR-ABL1 fusion
ALL
imatinib
Sensitive: A1 - Approval
No biomarker
CML
omacetaxine mepesuccinate
Sensitive: A1 - Approval
CD22 positive
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive: A1 - Approval
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive: A1 - Approval
CD20 expression
CLL
rituximab-arrx
Sensitive: A1 - Approval
BCR-ABL1 T315I
CML
ponatinib
Sensitive: A1 - Approval
BCR-ABL1 T315I
ALL
ponatinib
Sensitive: A1 - Approval
No biomarker
ALL
blinatumomab
Sensitive: A1 - Approval
No biomarker
B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive: A1 - Approval
No biomarker
AML
venetoclax
Sensitive: A1 - Approval
No biomarker
CML
ponatinib
Sensitive: A1 - Approval
TP53 mutation
CLL
venetoclax
Sensitive: A1 - Approval
No biomarker
CLL
Truxima (rituximab biosimilar)
Sensitive: A1 - Approval
No biomarker
CLL
Rixathon (rituximab biosimilar)
Sensitive: A1 - Approval
No biomarker
CLL
Ruxience (rituximab biosimilar)
Sensitive: A1 - Approval
No biomarker
CLL
venetoclax + rituximab
Sensitive: A1 - Approval
Chr del(17p)
CLL
venetoclax
Sensitive: A1 - Approval
No biomarker
CLL
zanubrutinib
Sensitive: A1 - Approval
BCR-ABL1 fusion
ALL
ponatinib
Sensitive: A1 - Approval
ABL1 T315I
CML
ponatinib
Sensitive: A1 - Approval
Chr t(1;16)(q12;q11.2)
CML
ponatinib
Sensitive: A1 - Approval
No biomarker
CLL
ibrutinib
Sensitive: A1 - Approval
No biomarker
CLL
ibrutinib + obinutuzumab
Sensitive: A1 - Approval
No biomarker
CLL
obinutuzumab
Sensitive: A1 - Approval
No biomarker
T Acute Lymphoblastic Leukemia
nelarabine
Sensitive: A1 - Approval
BCR-ABL1 fusion
ALL
dasatinib
Sensitive: A1 - Approval
No biomarker
CLL
rituximab
Sensitive: A1 - Approval
No biomarker
CLL
ofatumumab
Sensitive: A1 - Approval
CD19 positive
ALL
blinatumomab
Sensitive: A1 - Approval
No biomarker
AML
decitabine
Sensitive: A1 - Approval
No biomarker
Hairy Cell Leukemia
cladribine
Sensitive: A1 - Approval
Chr t(15;17)
Acute Promyelocytic Leukemia
arsenic trioxide
Sensitive: A1 - Approval
PML-RARA fusion
Acute Promyelocytic Leukemia
arsenic trioxide
Sensitive: A1 - Approval
CD20 positive
CLL
rituximab
Sensitive: A1 - Approval
No biomarker
CLL
venetoclax
Sensitive: A1 - Approval
No biomarker
CLL
rituximab/hyaluronidase
Sensitive: A1 - Approval
No biomarker
CML
busulfan
Sensitive: A1 - Approval
No biomarker
ALL
mercaptopurine
Sensitive: A1 - Approval
No biomarker
AML
azacitidine
Sensitive: A1 - Approval
No biomarker
CMML
azacitidine
Sensitive: A1 - Approval
BCR-ABL1 fusion
CML
nilotinib
Sensitive: A1 - Approval
Chr del(17p)
CLL
ibrutinib
Sensitive: A1 - Approval
No biomarker
CLL
obinutuzumab + acalabrutinib
Sensitive: A1 - Approval
No biomarker
CLL
obinutuzumab
Sensitive: A1 - Approval
No biomarker
CLL
acalabrutinib
Sensitive: A1 - Approval
IDH1 mutation
AML
ivosidenib
Sensitive: A1 - Approval
BCR-ABL1 fusion
CML
bosutinib
Sensitive: A1 - Approval
Chr del(17p)
CLL
rituximab + idelalisib
Sensitive: A1 - Approval
TP53 mutation
CLL
rituximab + idelalisib
Sensitive: A1 - Approval
Chr del(17p)
CLL
acalabrutinib
Sensitive: A1 - Approval
TP53 mutation
CLL
acalabrutinib
Sensitive: A1 - Approval
No biomarker
CLL
alemtuzumab
Sensitive: A1 - Approval
No biomarker
ALL
vincristine liposomal
Sensitive: A1 - Approval
No biomarker
Childhood B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive: A1 - Approval
No biomarker
Hairy Cell Leukemia
moxetumomab pasudotox
Sensitive: A1 - Approval
CD19 positive
B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive: A1 - Approval
TP53 mutation
CLL
idelalisib + ofatumumab
Sensitive: A1 - Approval
Chr del(17p)
CLL
idelalisib + ofatumumab
Sensitive: A1 - Approval
No biomarker
CLL
rituximab + idelalisib
Sensitive: A1 - Approval
No biomarker
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive: A1 - Approval
No biomarker
CLL
duvelisib
Sensitive: A1 - Approval
No biomarker
AML
idarubicin hydrochloride
Sensitive: A1 - Approval
CD20 positive
CLL
Ruxience (rituximab biosimilar)
Sensitive: A1 - Approval
No biomarker
ALL
recombinant Erwinia asparaginase
Sensitive: A1 - Approval
No biomarker
CLL
bendamustine
Sensitive: A1 - Approval
No biomarker
CLL
PCR
Sensitive: A2 - Guideline
Chr del(17p)
CLL
ofatumumab
Sensitive: A2 - Guideline
No biomarker
CLL
FCR
Sensitive: A2 - Guideline
TP53 mutation
CLL
rituximab + alemtuzumab
Sensitive: A2 - Guideline
Chr del(17p)
CLL
rituximab
Sensitive: A2 - Guideline
BCR-ABL1 V299L
ALL
dasatinib
Resistant: A2 - Guideline
IDH2 mutation
AML
venetoclax
Sensitive: A2 - Guideline
IDH1 mutation
AML
venetoclax
Sensitive: A2 - Guideline
BCR-ABL1 F317I
ALL
dasatinib
Resistant: A2 - Guideline
BCR-ABL1 T315I
ALL
dasatinib
Resistant: A2 - Guideline
TP53 mutation
CLL
venetoclax + rituximab
Sensitive: A2 - Guideline